Survival of adult patients with acute myeloid leukemia at the Hematology Department at Hospital Pablo Tobón Uribe between 2004 and 2010
Article Sidebar
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Downloads
Societal impact
Main Article Content
Abstract
Objective: To describe survival of AML patients at Hospital Pablo Tobón Uribe (HPTU) between January 2004 and June 2010.
Methods: An observational-descriptive case series in AML patients diagnosed and treated at HPTU between 2004 and 2010.
Results: Fifty-three cases of AML, 62.2% women. The median age was 55 years. Median WBC at diagnosis was 9,300. 5 cases (9.43%) were secondary to myelodysplastic syndromes. 51 patients (96.22%) received chemotherapy. The most common treatment regimen was idarubicin plus cytarabine 7x3 in 39 patients (73.58%). 28 patients (52.8%) achieved complete response to induction chemotherapy. 3 patients underwent allogeneic transplantation. 5 patients died during induction, 3 of them over 60 years. The median overall survival was 348 days. The median disease-free survival was 404 days. The overall survival rate at one year was 49%.
Conclusions: Series of 53 adult patients with AML. We found similar overall survival times as those reported in previous studies worldwide.
Article Details
References
Stone RM, O’Donnell MR, Sekeres MA. Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program.2004:98-117.
Burnett A, Wetzler M, Löwenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011 Feb 10;29(5):487-94.
Roboz GJ. Novel approaches to the treatment of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program.2011:43-50.
Mrózek K, Bloomfield CD. Chromosome aberrations, gene ,mutations and expression changes, and prognosis in adult acute myeloid leukemia. Hematology Am SocHematol Educ Program.2006:169-77.
Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC; 2008.
Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325-4336.
Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, et al.Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003 Dec 15;21(24):4642-9.
Dekkers OM, Egger M, Altman DG, Vandenbroucke JP. Distinguishing case series from cohort studies. Ann Intern Med. 2012 Jan 3;156(1 Pt 1):37-40.
Derolf AR, Kristinsson SY, Andersson TM, Landgren O, Dickman PW, Björkholm M. Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. Blood. 2009 Apr 16;113(16):3666-72.
Duque-Sierra L, Restrepo-Perdomo C, ZapataCárdenas A, Duque-Ortega JG, Donado-Gómez J, Mejía G. Características morfológicas, citogenéticas e inmunofenotipicas de pacientes con leucemia mieloide aguda. Medellin, Colombia. ACIMEL. 2006;11(2): 72-
Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood.2010 Jan 21;115(3):453-74.
García JS, Rosales J, Duque J, Abello V, Ramírez C, Solano MH, et al. Colombian Consensus Of Hematology And Oncology On Diagnoses And Treatment Of Acute Myelocytic Leukemia In Adult Patients. Rev Colomb Cancerol. 2006;10(4):223-233.
Hamadani M, Awan FT. Remission induction, consolidation and novel agents in development for adults with acute myeloid leukaemia. Hematol Oncol.2010 Mar;28(1):3-12.
Juliusson G, Antunovic P, Derolf A, Lehmann S, Möllgård L, Stockelberg D, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009 Apr 30;113(18):4179-87
Juliusson G, Lazarevic V, Hörstedt AS, Hagberg O, Höglund M; Swedish Acute Leukemia Registry Group. Acute myeloid leukemia in the real world: why population-based registries are needed. Blood.2012 Apr 26;119(17):3890-3899.